Use of antipsychotics in the elderly

International Journal of Psychiatry in Clinical Practice

Volumn 2, Issue SUPPL. 1, 1998, Pages

  Sciolla, Andrés ^a   Jeste, Dilip V ^b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOZAPINE; CYTOCHROME P450; CYTOCHROME P450 INHIBITOR; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; SERTINDOLE;

ADVERSE DRUG REACTION; AGED; AGRANULOCYTOSIS; ANTICHOLINERGIC EFFECT; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COGNITIVE DEFECT; CONFUSION; CONSTIPATION; DELIRIUM; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYMPTOM; HUMAN; KIDNEY DISEASE; LIVER DISEASE; MAINTENANCE THERAPY; PARKINSON DISEASE; PRIORITY JOURNAL; PSYCHOSIS; SCHIZOPHRENIA; SIDE EFFECT; SOMNOLENCE; TARDIVE DYSKINESIA; URINE RETENTION; VERTIGO; VISUAL IMPAIRMENT; XEROSTOMIA;

EID: 0031971781     PISSN: 13651501     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. Naranjo CA, Herrmann N, Mittmann N, Bremner KE (1995) Recent advances in geriatric psychopharmacology. Drugs Aging 7:184-202.
2. Reynolds GP (1994) Antipsychotic drug mechanisms and neurotransmitter systems in schizophrenia. Acta Psychiatr Scand 89: 36-40.
3. Leysen JE, Janssen PF, Heyler L et al (1998) Receptor interactions of new antipsychotics: Relation to pharmacodynamics and clinical effects. Int J Psyh Clin Practice 2(Suppl 1): S3-S17.
4. Kane JM, Woerner M, Lieberman J (1988) Tardive dyskinesia: prevalence, incidence, and risk factors. J Clin Psychopharmacol 8: 52S-56S.
5. Jeste DV, Caligiuri MP, Paulsen JS et al (1995) Risk of tardive dyskinesia in older patients: a prospective longitudinal study of 266 patients. Arch Gen Psychiatry 52: 756-65.
6. Fenton WS, Wyatt RJ, McGlashan TH (1994) Risk factors for spontaneous dyskinesia in schizophrenia. Arch Gen Psychiatry 51: 643-50.
7. McCreadie RG, Thara R, Kamath S et al (1996) Abnormal movements in never-medicated Indian patients with schizophrenia. Br J Psychiatry 168: 221-6.
8. Sandyk R, Kay SR, Awerbuch GI (1993) Subjective awareness of abnormal involuntary movements in schizophrenia. Int J Neurosci 69: 1-20.
9. Caligiuri MP, Lacro JP, Rockwell E et al (1997) Incidence and risk factors for severe tardive dyskinesia in older patients. Br J Psychiatry 171: 148-53.
10. Sweet RA, Mulsant BH, Gupta B et al (1995) Duration of neuroleptic treatment and prevalence of tardive dyskinesia in late life. Arch Gen Psychiatry 52: 478-86.
11. Russell RW (1996) Continuing the search for cholinergic factors in cognitive dysfunction. Life Sci 58: 1965-70.
12. Jerusalinsky D, Kornisiuk E, Izquierdo I (1997) Cholinergic neurotransmission and synaptic plasticity concerning memory processing. Neurochem Res 22: 507-15.
13. Meador KJ, Moore E, Nichols ME (1993) The role of cholinergic systems in visuospatial processing and memory. J Clin Exp Neuropsychol 15: 832-42.
14. Perry EK, Perry RH (1995) Acetycholine and hallucinations: disease-related compared to drug-induced alterations in human consciousness. Brain Cogn 28: 240-58.
15. Yeomans JS (1995) Role of tegmental cholinergic neurons in dopaminergic activation: antimuscarinic psychosis and schizophrenia. Neuropsychopharmacol 12: 3-16.
16. Feinberg M (1993) The problems of anticholinergic adverse effects in older patients. Drugs Aging 3: 335-48.
17. Keks NA (1996) Minimizing the non-extrapyramidal side-effects of antipsychotics. Acta Psychiatr Scand 389: 18-24.
18. Lewander T (1996) Neuroleptics and the neuroleptic-induced deficit syndrome. Acta Psychiatr Scand 89: 8-13.
19. Dilsaver SC (1993) Antipsychotic agents: a review. Am Fam Physician 47: 199-204.
20. Kuller L, Borhani N, Furberg C (1994) Prevalence of subclinical atherosclerosis and cardiovascular disease and association with risk factors in the Cardiovascular Health Study. Am J Epidemiol 139: 1164-79.
21. Center for Disease Control (1997) Prevalence of cardiovascular disease risk-factor clustering among persons aged ≥45 years -Louisiana 1991-1995. MMWR 46: 585-8.
22. Gregory C, McKenna P (1994) Pharmacological management of schizophrenia in older patients. Drugs Aging 5: 254-62.
23. Reeder BA, Liu L, Horlick L (1996) Sociodemographic variation in the prevalence of cardiovascular disease. Can J Cardiol 12: 271-7.
24. Liao D, Cooper L, Cai J et al (1997) The prevalence and severity of white matter lesions, their relationship with age, ethnicity, gender, and cardiovascular disease risk factors: the ARIC study. Neuroepidemiol 16: 149-62.
25. Campos-Outcalt D, Ellis J, Aickin M et al (1995) Prevalence of cardiovascular disease risk factors in a southwestern Native American tribe. Public Health Rep 110: 742-8.
26. Umbricht D, Kane JM (1996) Medical complications of new antipsychotic drugs. Schizophr Bull 22: 475-83.
27. Lennard MS (1993) Genetically determined adverse drug reactions involving metabolism. Drug Safety 9: 60-77.
28. Jackson DM, Ryan C, Evenden J, Mohell N (1994) Preclinical findings with new antipsychotics agents: what makes them atypical? Acta Psychiatr Scand 380: 41-8.
29. Lemmens P, Brecher M, Van Baelen B (1997) Tolerability and cardiovascular safety of risperidone, (Poster) 6th World Congress of Biological Psychiatry, Nice, France, June 22-27.
30. Borison RL (1996) The role of cognition in the risk-benefit and safety analysis of antipsychotic medication. Acta Psychiatr Scand 389:5-11.
31. Green MF, Marshall BD, Wirshing WC et al (1997) Does risperidone improve verbal working memory in treatment-resistant schizophrenia? Am J Psychiatry 154: 799-804.
32. Rossi A, Mancini F, Stratta P et al (1997) Risperidone, negative symptoms and cognitive deficit in schizophrenia: an open study. Acta Psychiatr Scand 95: 40-3.
33. Stip E, Lussier I (1996) The effect of risperidone on cognition in patients with schizophrenia. Can J Psychiatry 41: 35S-40S.
34. Ring BJ, Binkley SN, Vandenbranden M, Wrighton SA (1996) In vitro interaction of the antipsychotic agent olanzapine with human cytochromes P450 CYP2C9, CYP2C19, CYP2D6 and CYP3A. Br J Clin Pharmacol 41: 181-6.
35. Jeste DV, Eastham JH, Lacro JP et al (1996) Management of late-life psychosis. J Clin Psychiatry 57 (Suppl 3): 39-45.
36. Alvir JMJ, Lieberman JA, Safferman AZ et al (1993) Clozapine-induced agranulocytosis: incidence and risk factors in the United States. N Engl J Med 329: 162-7.
37. Jeste DV, Eastham JH, Gierz M, et al (1997) Use of risperidone in the elderly. In: The art of rational risperidone therapy, (ed FJ Ayd) 147-167. Ayd Medical Communications, Baltimore MD.
38. Andreasen NC, Olsen S (1982) Negative vs positive schizophrenia: definition and validation. Arch Gen Psychiatry 39: 789-94.
39. Andreasen NC (1984) The scale for the assessment of positive symptoms (SAPS). University of Iowa, Iowa City.
40. Andreasen NC (1982) Negative symptoms in schizophrenia: definition and reliability. Arch Gen Psychiatry 39: 784-8.
41. Folstein MF, Folstein SE, McHugh PR (1975) Mini-Mental State: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12: 189-98.
42. Borison RL, Davidson M, Berman I (1994) Risperidone treatment in elderly patients with schizophrenia or dementia (poster). American Psychiatric Association 46th Institute of Hospital and Community Psychiatry. APA, Washington, DC.
43. Berman I, Merson A, Allan E et al (1995) Effect of risperidone on cognitive performance in elderly schizophrenic patients: a double-blind comparison with haloperidol (poster). New Clinical Drug Evaluation Unit 35th Annual Meeting, Florida, USA.
44. Wolters EC, Jansen ENH, Tuynman-Qua HG, Bergmans PLM (1996) Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson's disease. Neurology 47: 1085-7.
45. Zaleon CR, Guthrie SK (1994) Antipsychotic drug use in older adults. Am J Hosp Pharm 51: 2917-43.
46. Wilcox J (1994) Divalproex sodium in the treatment of aggressive behavior. Ann Clin Psychiatry 6: 17-20.
47. Frykholm B (1985) Clonazepam - antipsychotic effect in a case of schizophrenia-like psychosis with epilepsy and in three cases of atypical psychosis. Acta Psychiatr Scand 71: 539-42.
48. Chouinard G, Annable L, Turnier L et al (1993) A double-blind randomized clinical trial of rapid tranquilization with IM clonazepam and IM haloperidol in agitated psychotic patients with manic symptoms. Can J Psychiatry 38: S114-S121.
49. Sunderland T (1996) Treatment of the elderly suffering from psychosis and dementia. J Clin Psychiatry 9: 53-6.
50. Bertilsson L (1995) Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochrome P.450 (CYP) 2D6 and 2C19. Clin Pharmacokinet 29: 192-209.
51. Pollock BG, Mulsaht BH, Sweet RA et al (1995) Prospective cytochrome P450 phenotyping for neuroleptic treatment in dementia. Psychopharmacol Bull 31: 327-31.
52. Brosen K (1996) Drug-metabolizing enzymes and therapeutic drug monitoring in psychiatry. Ther Drug Monit 18: 393-6.
53. Pitner JK, Mintzer JE, Pennypacker LC, Jackson CW (1995) Efficacy and adverse effects of clozapine in four elderly psychotic patients. J Clin Psychiatry 56: 180-5.
54. Borison RL (1996) Changing antipsychotic medication: guidelines on the transition to treatment with risperidone: The Consensus Study Group on Risperidone Dosing. Clin Ther 18: 592-607.
55. Gilbert PL, Harris MJ, McAdams LA, Jeste DV (1995) Neuroleptic withdrawal in schizophrenic patients. Arch Gen Psychiatry 52: 173-188.